Literature DB >> 2451458

Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin.

N R Ferreri1, W C Howland, D D Stevenson, H L Spiegelberg.   

Abstract

The levels of leukotriene C4 (LTC4), leukotriene B4 (LTB4), prostaglandin E2 (PGE2), and histamine were measured in nasal lavage fluids obtained from aspirin-sensitive, desensitized aspirin-sensitive, and aspirin-insensitive asthmatics and normal volunteers before and after ingestion of aspirin. Increased levels of LTC4 and histamine were associated with significant decreases in the FEV1 for 3 of 4 aspirin-sensitive asthmatics who had both naso-ocular and bronchospastic reactions to aspirin. In contrast, no increase in LTC4 or histamine release was detected in aspirin-sensitive asthmatics who had only bronchospastic reactions to aspirin. No significant decreases in PGE2 levels or increases in LTB4 levels were detected during these reactions to relatively low doses of aspirin regardless of the clinical symptoms, nor was any increase in mediator release apparent in lavage fluids from normal donors, aspirin-insensitive asthmatics, and desensitized aspirin-sensitive subjects before or after various doses of aspirin. Levels of PGE2 decreased in nasal secretions from normal volunteers, aspirin-insensitive asthmatics, and desensitized aspirin-sensitive subjects after ingestion of 650 mg of aspirin. These decreases were not associated with increased LTC4 or LTB4 or with histamine release, decreased FEV1, or naso-ocular symptoms. In addition, reductions of PGE2 release were similar for normal and desensitized aspirin-sensitive volunteers (63 +/- 11 versus 61 +/- 10%, respectively). The data demonstrate that LTC4 and histamine are released into nasal secretions of aspirin-sensitive asthmatics with naso-ocular and bronchospastic reactions after ingestion of low doses of aspirin without a decrease in the levels of PGE2 and suggest that LTC4 and histamine contribute to the naso-ocular and bronchospastic symptoms characteristic of reactions to aspirin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451458     DOI: 10.1164/ajrccm/137.4.847

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  36 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis.

Authors:  R A Simon
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

3.  Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma.

Authors:  Y Nakamura; M Hoshino; J J Sim; K Ishii; K Hosaka; T Sakamoto
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 4.  Aspirin-induced asthma.

Authors:  L T Vaszar; D D Stevenson
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

5.  Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma.

Authors:  A r Sousa; R Pfister; P E Christie; S J Lane; S M Nasser; M Schmitz-Schumann; T H Lee
Journal:  Thorax       Date:  1997-11       Impact factor: 9.139

6.  Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects.

Authors:  S Nasser; P E Christie; R Pfister; A R Sousa; A Walls; M Schmitz-Schumann; T H Lee
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

7.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

8.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  Ketorolac-induced bronchospasm in an aspirin-intolerant patient.

Authors:  A H Chen; C R Bennett
Journal:  Anesth Prog       Date:  1994

Review 10.  Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs).

Authors:  Ronald A Simon; Jennifer Namazy
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.